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Application of post-genomic techniques in
dog cancer research
F. Ceciliani,* P. Roccabianca, C. Giudice and C. Lecchi
Omics techniques have been widely applied to veterinary science, although mostly on farm animal
productions and infectious diseases. In canine oncology, on the contrary, the use of omics
methodologies is still far behind. This review presents the most recent achievement in the application of
postgenomic techniques, such as transcriptomics, proteomics, and metabolomics, to canine cancer
research. The protocols to recover material suitable for omics analyses from formalin-fixed, paraﬃn-
embedded tissues are presented, and omics applications for biomarker discovery and their potential for
cancer diagnostics in veterinary medicine are highlighted.
1. Introduction
Cancer is one of the leading causes of death in dogs. Approxi-
mately 50% of dogs 10 years or older develop cancer and in 25%
it is considered the cause of death (http://www.acfoundation.
org/).1 As the average lifespan continues to rise in dogs, cancer
in pet animals is expected to become one of the most relevant
health problems in veterinary medicine. Certain spontaneous
dog cancers are particularly attractive as a model for the
corresponding human disease. Noteworthy, dogs are geneti-
cally close to humans; they share the same environmental
challenges, receive a high level of healthcare,2 and many
naturally occurring cancers are the same as for humans.3,4
Moreover, combination chemotherapy and radiation therapy
are now commonly administered to companion animals and
responsiveness to conventional antitumour therapies shares
many similarities among humans and dogs.5,6 Additionally,
in specific breeds, such as boxers and golden retrievers,
the incidence of tumours such as lymphoma is even higher
(one every four and one every eight, respectively),7–9 providing
important information about a hereditary and genetic basis for
cancer.
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Cancer is a complex disease. Eﬀective therapy and positive
prognosis rely on early diagnosis and adequate classification
of cancer type, providing information necessary for targeted
therapies.10 In human medicine, the application of high-
throughput omics has been proven useful to investigate cancer-
ogenesis. In canine oncology, on the contrary, the application
of omics techniques is still far behind. We present here the
most recent achievement in the application of omics techni-
ques, including proteomics, transcriptomics, and metabolo-
mics, in canine cancer research. Although very informative
about cancer pathogenesis, genomics studies on chromosome
modifications in dog cancer fall outside the scope of this paper
and have been recently reviewed elsewhere.2,11
2. Postgenomic techniques applied to
canine oncology
Proteomic and postgenomic applications in veterinary medi-
cine are increasing exponentially although most of them have
been carried out on farm animals.12 Studies in companion
animals mostly focus on pathogenesis and diagnostics of
infectious diseases and cancer.11,13
To date, few databases are made available for the dog species.
The dog genome was published in 2005,14 and an improved
version was recently published.15 Table 1 presents an updated
list of canine protein and DNA databases.
Table 2 presents the proteomic reference maps for canine
fluids, which provide the prerequisite for omics investigations.
The proteomic maps of canine biological fluids have been
also recently reviewed.27
Next generation sequencing (NGS) (Fig. 1) and gel-free high
throughput proteomics (Fig. 2) stand at the cutting edge of the
techniques currently used for data acquisition in molecular
pathogenesis and biomarker research in cancer and are prob-
ably poised to replace microarrays (Fig. 3) and two-dimensional
gel electrophoresis (2DGE) (Fig. 2) in the years to come.
So far, microarrays and 2DGE are still the workhorses among
omics applied to canine oncology, and they should be regarded as
complementary to NGS and gel-free proteomics.28,29 A thorough
review of methods currently available for omics studies, including
their potentials and limitations in veterinary medicine, has been
published.30 Not surprisingly, omics techniques were applied
mainly to the study of the most common cancer types in dogs,
namely mammary gland carcinoma and blood malignancies,
although other types of cancer, such as bladder adenocarcinoma,
mastocytoma, and osteosarcoma, have been investigated, taking
advantage of high throughput omics techniques.
3. Mammary gland tumours
Mammary gland tumours are considered the most common
malignancies in female dogs of geographical areas where
spaying is retarded or not routinely performed.31 Prevalence is
Table 1 Protein and DNA databases dedicated to dogs
Data bank Web address
Phylogenetic
mitochondrial DNA
tree16
http://clf.mtdna.tree.cm.umk.pl/
Dog Genome SNP
Database (DoGSD)17
http://dogsd.big.ac.cn/
Entrez database http://www.ncbi.nlm.nih.gov/projects/map
view/static/dogsearch.html
CaniSome18 http://www.crb.ucp.pt/salivatec/canisome/
Non coding RNA19
Dog assembly and
gene annotation15
http://genome.ucsc.edu/cgi-bin/hgGate
way?hgsid=480309867_Zct4maej2YfZU4tPaEYm
VEO6WMxp
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up to 0.2%, and death usually occurs following metastatic disease.
The incidence of canine mammary gland neoplasms is estimated
at 50% of all neoplasms in this species.32 Spontaneously occurring
mammary gland cancer provides a good model for human breast
cancer.33–36 The knowledge of the molecular aspects of mammary
gland tumours in dog has been very recently reviewed.37,38 A recent
investigation analysed in molecular depth the homologies and the
differences between mammary gland cancers of dogs and humans
by combining whole-genome sequencing, whole-exome sequen-
cing, RNA sequencing, and microarray analysis of simple and
complex carcinomas. The authors found that canine simple
carcinomas presented genomic aberrations, and were molecularly
similar to human breast carcinomas. In addition, canine complex
carcinomas were characterised by modification of genes involved
in chromatin remodelling, suggesting that the development of this
group of cancers may be related to epigenomic alterations.39
Omics in the characterisation of mammary gland-derived
tumour cell lines
Tumour-derived cell lines are widely used as the primary
experimental model system to study tumour pathogenesis
and therapy. The transcriptome of primary tumour cell cultures
has been demonstrated as corresponding to transcriptome of
parental tumour tissues.40 Five mammary adenocarcinoma cell
lines, namely PL-20, CMT-W1, CMT-W2, P114, and CMT-U27,
were selected for gene expression studies,41 sorting the cells in
(a) high proliferation potential, (b) high antiapoptotic
potential, and (c) high metastatic potential. DNA microarray
was used to identify associations between cell potential and
gene expression. Consistent with phenotypical features, high
proliferation rate potential was associated with the expression
of genes encoding for growth hormone and ghrelin, high
antiapoptotic potential was associated to BCR-related genes
and TMD1, and metastatic potential was associated to elevated
expression of PGOP, SEMA3B, and STM1. The reliability of
mammary cell lines as a model to study mammary gland
adenocarcinoma allowed investigation of the impact of proges-
terone on the development of mammary cancer, by comparing
diﬀerences in gene expression between cells derived from progestin-
induced hyperplasia, spontaneous mammary tumours, and healthy
mammary tissues.42 The expression pattern of progestin-induced
canine hyperplasia was characterised by upregulation of 50 genes
including, among the others, PCNA and RAS family members.
Moreover, 75 genes were found to be downregulated. The gene
expression profile of the canine mammary tumour cell line was
diﬀerent: 69 genes were found to be upregulated. This group
included genes involved in cell adhesion and motility, such as
CCL4L1 and Fibronectin 1, and proliferation, such as b-catenin 1. An
additional 110 genes were also found to be downregulated.
Working with in vitro cell systems provides the unique
opportunity to identify the role of each individual component
in the onset, development, and progression of malignant
phenotypes, as well as the interaction with other cell types,
such as white blood cells and fibroblasts. Co-culturing canine
mammary cell lines with macrophages allowed demonstration
Table 2 Dog proteomic maps
Tissue Technique
Urinary proteome20 LC-MS/MS
Blood serum21 2D/MS
Bronchoalveolar lavage fluid22 2-DIGE/MS
Cerebrospinal fluid23 2D/MALDI-TOF
Mammary cell line24 2D/MALDI-TOF/TOF-MS
Tears25 1D/MALDI-TOF-MS/MS
Tears26 2D/MALDI-TOF
LC-MS/MS, liquid chromatography-mass spectrometry; 2D/MS, 2D gel
electrophoresis/mass spectrometry; 2-DIGE/MS, 2-D fluorescence diﬀer-
ence gel electrophoresis/mass spectrometry; 2D/MALDI-TOF, 2D gel
electrophoresis/matrix-assisted laser desorption ionisation-time of flight.
Fig. 1 RNA-seq workflow. The workflow begins with poly-A-mRNA purification using poly-T beads. The RNA is cleaved into fragments of 100–200 bp
by enzymatic reaction or by chemical hydrolysis. The fragmented RNA is converted into a double-stranded cDNA library. RNA fragments are hybridised
and ligated to an adapter mixture using the RNA ligase. The adaptors’ linked RNA is converted to single strand cDNA using reverse transcriptase and
purified. The cDNA library is finally enriched with PCR and then purified. During the PCR step it is also possible to introduce specific short DNA sequences
acting as barcodes to identify different samples. The final product consists of dsDNA molecules of 200–300 bp containing the copies of the RNAs
present in the original sample surrounded by adapters and creates the final cDNA library.
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of the impact of the Wnt pathway in cancer transformation.43,44
After co-culturing with macrophages, cancer cells express some
macrophage-specific antigens, such as CD14, CD64, CD163,
and CSFR, as well as macrophages attracting proteins. Remark-
ably, macrophages co-cultured with cancer cells produce
ligands involved in Wnt pathway (Wnt5b, Wnt7a, and Wnt7b).
Diﬀerences in microRNA expression have indicated that a
switch from canonical Wnt to noncanonical Wnt pathway also
occurs, providing evidence that the interplay between intratu-
moural macrophages and mammary cancer cells may also rely
on epigenetic regulation. Epigenetic regulation of cancer cell
has also been recently investigated using mammary cancer
Fig. 2 Proteomic workflow. The proteomic workflow starts with the extraction of proteins from tissues or cell cultures. The protein fractionation may be
either electrophoretic (upper panel), or chromatography (lower panel). The electrophoretic fractionation system former is applied to intact proteins.
Conventional 2DE involves separation of protein by means of isoelectric focusing in the first dimension, which is thereafter followed by sodium dodecyl
sulphate electrophoresis in the second dimension. Both dimensions are carried out in a polyacrylamide gel matrix. The proteins migrate on 2D gels as
spots according to an isoelectric point and apparent molecular weight. The resulting spots can be excised directly from the gel for characterisation by
mass spectrometry (MS). The chromatographic fractionation system includes a trypsin digestion of the protein extract to generate peptides that can be
further fractionated by high performance liquid chromatography (HPLC). The chromatography eluate flows into an ESI-MS (LC-MS). The MS records the
mass of analytes and also isolates and fragments peptide ions (MS/MS, or tandem MS) to generate information about structure.
Fig. 3 Microarray workflow. The workflow starts with RNA purification and retrotranscription to double-stranded cDNA. After purification, cDNA are
fluorescently labelled with distinct fluorescent dyes—such as, Cy-3 (green) and Cy-5 (red)—and detected by hybridisation onto immobilised DNA probes
on the microarray. Each sample sequence (target) hybridises to the complementary strand on the array (probe) allowing confirmation of the presence of
a target gene. Multiple DNA probes are spotted on a thin support—such as, silicium, glass, or polymers—with each one being specific for a DNA or RNA
target sequence.
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stem-like cells.45 MicroRNA profiling was carried out and found
that 33 microRNA were dysregulated, the most relevant being
miR-451 (upregulated) and miR-135b (downregulated). Both
these microRNAs were already found to be dysregulated in
human counterpart,46,47 although in mammary cancer cells
the miR-135b was found to be mostly upregulated.
Carcinoma-associated fibroblasts provide the main cancer
stromal structure.48 Gene expression studies of cancer cell lines
co-cultured with carcinoma-associated fibroblasts have demon-
strated that 100 genes were upregulated in cancer cells as
compared to individual cell lines.49 This group of genes codes
for proteins involved in cell adhesion, such as chondroadherin,
CLEC7A, protocadherin-19, desmoplakin, and VCAM-1, and
angiogenesis, such as EMT. A group of 106 genes was also
found to be downregulated; this list includes an antiangiogenic
protein (ADAMTS15), and a cell adhesion molecule (CADM4).
Proteomic profiling of in vitro adenocarcinoma cells has been
also carried out. A mammary adenocarcinoma cellular line was
established and proteome was characterised by 2-DGE and
MALDI-TOF,24 providing the background for a study aimed to
identify potential autoantigens by applying serological proteome
analysis (SERPA).50–52 Proteins derived from tumour cancer lines
were separated by 2-DGE and blotted onto PVDF membranes,
and incubated with serum obtained from dogs with mammary
gland tumours. Four autoantigens were identified, namely
Mn-SOD, trioso phosphate isomerase, alpha-enolase, and phos-
phoglycerate mutase 1, and results were validated with immuno-
histochemistry and Western blotting. These findings reported
for the first time an autoantibody response in canine mammary
adenocarcinoma, confirming what has been previously found for
human breast cancer.
Cancer progression and development of metastatic clones
One of the most striking features of mammary adenocarcinoma
is the development of metastatic clones, which eventually
causes patient death. A transcriptomic study compared lymph
node metastases with the corresponding non neoplastic
mammary tissue.53 A total of 730 genes were found to be
upregulated—including genes associated with cell cycle progres-
sion (cyclins/CDK, DNA replication genes), and metalloproteinases.
Conversely, 580 genes were found to be downregulated in meta-
static lymph nodes, including angiogenesis and adhesion
molecules, together with genes coding for seven proteinase
inhibitors. Regulators of mammary gland development—such
as hormone receptors, steroid metabolism, growth factor
receptors, genes associated with carbohydrate/lipid metabo-
lism, and genes involved in negative regulators of cell cycle
progression—were also downregulated, as well as trans-
membrane rectors, namely TGFBR2, PDGF1, VEGFR1, and
FGFR1, suggesting that the metastatic cell phenotype is less
diﬀerentiated as compared to the normal one.
The transcriptomic profile from canine adenocarcinoma
lines was compared with that of lines isolated from their
respective lung metastases.54 Fifteen genes, belonging to signal
transduction, developmental processing, and apoptosis path-
ways, were found to be upregulated in metastatic cell lines,
highlighting the role of growth hormone secretagogue receptor
(GHSR) as a candidate for pulmonary metastatic signature.
A second parallel study was carried out on 13 mammary
carcinomas with lymph node metastases and 14 carcinomas
without lymph node metastases.55 Results demonstrated that
metastatic carcinomas have 1011 diﬀerentially expressed genes
as compared with non metastatic carcinomas. Cell cycle check-
point genes and DNA damage repair genes were upregulated in
metastatic carcinoma, whereas growth factor receptor pathways
and cell diﬀerentiation genes were downregulated, somehow in
contrast with other findings previously reported.54 Adhesion-related
genes were also diﬀerentially regulated, and angiogenesis-related
genes were downregulated. Out of the 1011 diﬀerentially expressed
genes, 265 genes were also reported as dysregulated in human
breast cancer. Moreover, a significant overlap with human breast
cancer prognostic signature was also found, providing further
evidence that spontaneous cancer in bitches can be regarded as a
good model for the human counterpart.
Changes in gene expression in mammary cancer cell
lines after co-culturing with myeloid-derived suppressor cells
(MDSC) were recently investigated.56 Microarray analysis gene
expression revealed that 107 genes were significantly upregulated
in cell lines after MDSC treatment, most of them being involved in
inflammation, interleukin signalling pathway, and cytoskeletal
regulation. The study then focused on the IL-28/IL-28R pathway by
knocking down IL-28R, and demonstrated that treatment with
IL-28 promotes angiogenesis, epithelial–mesenchymal transition,
and enhances mammary tumour invasion and migration.
Beside transcriptomics, also proteomics approaches were
applied to obtain further insights into the molecular features of
metastatic progression. Two groups of canine mammary carci-
nomas, one group with metastasis to the regional lymph nodes
and one group without metastases, were compared by means of
2D-DIGE and diﬀerentially expressed spots were identified with
MALDI-TOF.57 Eleven proteins were found to be upregulated in
metastatic cancers. This group included proteins involved in
cell proliferation and division, such as EF1 delta and Ran/TC4-
binding proteins. Downregulated proteins in the metastatic
cancer group included vinculin and tropomyosin 1 (cell adhe-
sion) and c myosin light chain 2 and calretinin (cell motility).
Protein inhibitors were both up- and downregulated in the
metastatic cancer group (serpin 5 was upregulated, whereas
serpin B10 was downregulated). In addition, stress-related/
scavenger proteins were diﬀerentially regulated: TXNDC5 was
upregulated, and peroxiredoxin 6 was downregulated. The
expression of only five of the diﬀerentially expressed proteins
was validated by RT-PCR, suggesting that posttranscriptional
regulation of these molecules occurred. A comparison between
normal, benign, nonmetastatic and metastatic mammary gland
tumours was investigated by applying 2D-DIGE and MALDI-
TOF analysis.58 Although no linear changes in the expression
of individual proteins were detected during the progression
from adenoma to metastatic cancer, the results defined three
patterns: an adenoma pattern was characterised by changes in
the expression of 13 proteins, a carcinoma pattern with 9
diﬀerentially expressed proteins, and a metastatic carcinoma
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pattern, where 20 proteins were found to be diﬀerentially
expressed as compared to each of the two previous stages.
These results suggested that progression toward malignancy
was not linear, but followed a stepwise increase or decrease of
protein expression levels. Six proteins displayed a significant
change in their expression level, and four could be identified,
namely EF1 delta, vinculin, ferritin light polypeptide, and
hemopexin, highlighting their possible use as possible markers
for metastatic pattern.
Breast sarcomas are much more uncommon, and microar-
ray technology was applied to compare gene expression pat-
terns of mammary carcinoma with those of mammary gland
fibrosarcomas and osteosarcoma;59 focus was on homeobox
transcription factors, which were known to upregulate during
mammary gland tumours. As compared to other type of
mammary tumours, osteosarcomas exhibited an upregulation
of BMPs and gene associate with retinoic acid signalling.
Results were also validated by means of immunohistochemistry
and after stimulating an osteosarcoma cell line with BMP-2,
providing the background to demonstrate the importance of
BMPs protein expression in the development of osteosarcoma
mammary tumours.60
Biomarkers for early diagnosis and prognosis
Not surprisingly, several studies have been directed to identify
cancer biomarkers in serum of dogs aﬀected from mammary
adenocarcinoma. Given that the presence of circulating tumour
cells in peripheral blood provides relevant prognostic clues for
human breast cancer, a pilot study was carried out to identify
the presence of mRNA in circulating tumour cells. Two canine
carcinoma cell lines were diluted with blood from healthy
animals, and their transcriptomes were compared with those
of white blood cells collected from healthy animals (da Costa
et al., 2012),61 demonstrating that two genes, namely ATP8B1
and CRYAB, were the most sensitive genes; although AGR2,
IRX3, F3, and SLC1A1 were detected, the three last genes have
never been identified before.
4. Blood malignancies
Lymphomas are most common haematopoietic neoplasms in
dogs, being responsible for approximately 24% of all canine
cancer diagnoses.4 Canine lymphomas share several epidemio-
logical, biological, and clinical features with the human counter-
part, in particular the non-Hodgkin lymphomas,62–64 and its use
as a comparative model for human non-Hodgkin lymphoma has
been recently reviewed.65,66 A comparison between human and
dog lymph nodes forming diffuse large B-cell lymphoma67
demonstrated that the gene expression profile was similar. A
germinal centre phenotype could be differentiated from a post-
germinal centre phenotype in canine B-cell lymphoma, although
it was not evident, at a molecular level, how close this differ-
entiation in dog corresponded to the human germinal centre
B-cell and activated B-cell. Dog lymphoma also provided a model
to study the relationship between heritable factors and the
development of the disease (Fig. 4).9
Fig. 4 B-cell and T-cell prevalence of non-Hodgkin lymphoma among breeds. Breeds exhibit statistical diﬀerences between the reference population
(mixed bred dogs). Data are elaborated from Modiano et al.9
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Transcriptional profiling can be carried out from surgical
biopsies and from fine needle aspirations.68 Fine needle aspi-
rated samples have been used to compare—with diﬀerent
techniques (RNA-seq and microarray)—the changes in the
B-cell lymphoma transcriptome.69 The experiment focused on
the use of phosphatidylinositol 3-kinase (PI3-K) inhibitor. Both
RNA-seq and microarrays identified similar sets of expressed
genes in lymphoma, although RNA-seq was more sensitive.
A custom-designed microarray including genes involved in
the NF-kB pathways and other genes, which were previously
found to be dysregulated during lymphoma, was designed70 to
investigate gene expression in lymph nodes from dogs with
diﬀuse large B-cell lymphoma. Results were compared with
equivalent human samples. The most important finding was
that 54 NF-kB target genes were dysregulated in human lymphoma,
whereas 17 NF-kB target genes were diﬀerentially regulated in the
correspondent canine disease. Other canine genes indirectly related
to NF-kB were diﬀerently expressed; specifically, genes coding for
CD40LG, LCK, LTBR, and TNFSF11 were downregulated, while
genes coding for EIF2AK2 and MYD88 were upregulated.
A large canine lymphoma exome sequencing study has been
carried out on three dog breeds that spontaneously develop
lymphoma, namely boxers (T-cell), cocker spaniels (B-cell), and
golden retrievers (B- and T-cell).71 Recurrent mutations were
found in TRAF-MAP3K14, FBXW7, and POT1, with evident
similarities between B-cell lymphomas from golden retrievers
and cocker spaniels. T-cell lymphomas from boxers carried
mutations in the tumour suppressor PTEN-mTOR signalling
pathway. Mutations of the T-cell lymphomas from boxers and
golden retrievers did not overlap. Although almost 50% of the
mutated genes were found to be involved also in human
lymphoma, several mutations, such as those in NLRP family,
were new, and others, namely PSMA1 and KPNA2, were never
reported in human lymphoma, but have been observed in other
types of human cancer. Molecular profiling of samples from
naturally occurring lymphoma was carried out after RNA
isolation and microarray.72 Gene expression profiling allowed
for subdivision of the most common subtypes of canine
lymphoma73 into three molecular subgroups, namely high-
grade T-cell lymphoma, low-grade T-cell lymphomas, and
B-cell lymphomas. Gene signature identified 389 genes that
were diﬀerentially expressed between T-high grade and T-low
group, and 624 genes diﬀerentiated between B-cell and T-cell
lymphomas. Gene expression results supported the design of a
simple diagnostic platform relying on some genes, including
CD28 and ABCA5, diﬀerentiating T-cell from B-cell lymphomas,
and CCDC3 and SMOOC2 ratio diﬀerentiating T-low grade from
T-high grade lymphoma. Proteomics analysis was carried out by
2D electrophoresis followed by MALDI-TOF on lymph nodes
from lymphoma aﬀected animals before chemotherapy was
given.74 The authors found that at least four proteins were
diﬀerentially expressed between the proteomes of lymph nodes
of dogs with lymphoma as compared to those of healthy dogs.
Four proteins, namely prolidase, triosephosphate isomerase,
and glutathione S-transferase, were found to be downregulated,
whereas one protein, MCP, was upregulated. The importance of
MCP was recently confirmed also in transitional cell carcinoma
of urinary bladder cancer in dogs.75 Remarkably, this paper was
the first to identify MCP as cancer biomarker. Other studies on
diﬀerent human malignancies76–80 validated MCP as a cancer
biomarker, further supporting the use of dogs as useful models
for human cancer.
Studies on the serum proteome changes of canine lymphoma
have been carried out by combining ion exchange chromato-
graphy and surface-enhanced laser desorption ionisation (SELDI)
mass spectrometry. A classification and regression tree (CART)
bioinformatic algorithms discriminating spectral data of unknown
serum samples of lymphoma from nonlymphoma serum samples,
with an average result of sensitivity and specificity of 84% and
83%, respectively, was developed.81 The same approach was
followed in a previous investigation, which relied on the
comparison of peak amplitude to the spectra of healthy and
lymphoma-aﬀected dogs to identify protein peaks associated
with B-cell lymphoma.82
A protocol combining MS identification following 2-DGE of
serum proteins in dog was recently developed.21 The technique
was then applied to identify alterations in serum proteome of
dogs with multicentric lymphoma.83 Proteins were identified by
means of MS, after previous PAGE gel separation. The technique
detected 31 individual proteins, 10 of which were not previously
identified in the serum of healthy animals, including a2
Heremans-Schmid (HS) glycoprotein, haptoglobin, clusterin, a2
macroglobulin, apolipoprotein A1 precursor, apolipoprotein E,
a-antichymotrypsin, lipopolysaccharide binding protein, antith-
rombin III, and inter-a-trypsin inhibitor whereas one protein,
HMWK, was absent from the sera of all the three dogs with
lymphoma, as compared to the healthy dogs.
Proteomics also encompass methods that identify posttransla-
tional modification, such as glycosylation and phosphorylation.
Glycoproteomic techniques provide biomarkers in oncology84 and
lectin arrays have been recently developed to determine a glyco-
mic profiling of cancer.85 Only one glycoproteomic study has been
carried out in dogs, targeting glycosylation diﬀerences in diﬀuse
large B-cell lymphoma, and changes in fucosylated peptides were
quantified by Global Internal Standard Technology (GIST) stable
isotope peptide labelling.86 Briefly, tryptic peptides were generated
from serum samples of healthy and lymphoma-aﬀected dogs.87
Primary amines on peptides were then acylated with GIST isotope
labelling reagents, and fucosylated peptides sorted by lectin
binding aﬃnity chromatography. After deglycosylation and
fractionation, peptides were analysed and quantified with
MALDI-TOF. Pre-chemotherapy and post-chemotherapy glyco-
proteome profiles were also determined. Changes in fucosyla-
tion were found in more than 78.9% peptides from the
lymphoma serum samples as compared to those from healthy
dogs. A percentage of 61.15% decreased with remission, and
73% increased again during relapse of the disease. In addition,
individual peptides were compared, and 46 of them, which
were found to be similar across the treatment groups, increased
their concentration during lymphoma, and then decreased
after chemotherapy, to increase again during relapse. Although
the scope of the study was narrow (only three animals with
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lymphoma), the results demonstrated the potential of glyco-
peptide profiling biomarkers for the diagnosis and prognosis of
blood malignancies.
5. Mast cell tumours
The most frequent skin neoplasm of dogs is cutaneous mast
cell tumour (MCT), accounting for 7% to 21% of all canine skin
tumours.88 Several mutations of the KIT gene have been
identified,89,90 although only 9% to 17% of all MCTs actually
contain mutations at KIT.91,92 Given this background, MCT
cells were treated with the tyrosine kinase inhibitor masitinib,
aiming to identify changes in both transcriptome and proteome.93
Microarray-based transcriptome compared treated with untreated
cells along a time course. Changes in transcriptome showed that
most nuclear factors were downregulated after treatment with
masitinib, as well as genes associated with energy pathways and
stress. Masitinib also induced a downregulation of genes regu-
lated by p53, and an upregulation of genes associated with signal
transduction, namely T-cell receptor, insulin receptor, and steroid
hormone receptors. The changes in gene regulations were time
dependent: the number of dysregulated genes increased over the
time course. A parallel proteomics analysis was carried out. Most
diﬀerences were found in cells collected after 72 hours of treat-
ment with masitinib. Remarkably, mRNA expression from six of
the eight downregulated proteins was also found to be down-
regulated. Five of the 15 upregulated proteins were also found to
be upregulated at the gene expression level, whereas another four
were downregulated. Besides providing a wide source of potential
biomarkers to study the eﬀect of masitinib treatment, this study
also highlighted the pathways that the neoplastic cells are able to
activate (or diﬀerentially regulate) to replace KIT activity when its
signalling pathway is blocked.
2D-DIGE separation followed by identification by MALDI-
TOF identified diﬀerences between low-grade MCT, with a good
prognosis, and high-grade MCT, with a poor prognosis.90
Proteins associated with cellular stress response, such as
HSPA9, PDIA3, TCP1A and TCP1E, were upregulated in high-
grade MCT. Other proteins related to cell motility and meta-
stases, including WDR1, ANXA2, ANXA6 ACTB, and ACTR3,
were upregulated in high-grade MCT. One protein, TPSAB1, was
found to be downregulated in high-grade MCT, as well as
transferrin, the last one being downregulated also at gene level.
Albumin and ATIC were also diﬀerentially regulated (down- and
upregulated in MCT, respectively).
6. Urinary cancers
Bladder cancer comprises 2% of naturally occurring cancers
in dogs, with transition cell carcinoma (TCC; urothelial carci-
noma) being the most common type.94,95 Although it is
expected that bladder cancer will aﬀect more than 20 000 dogs
per year in the United States alone,95 the application of omics
techniques to investigate the molecular basis of this type of
cancer is still in its infancy. A comparative gene expression
analysis has provided molecular support to the possible use of
canine invasive urothelial carcinoma as a model for the equi-
valent human diseases compared with healthy controls and
human cancer samples, which in turn were compared to
normal bladders.96 Luminal and basal tumour subtypes were
associated with specific gene expression patterns. Two path-
ways were found to be particularly enriched, namely EGFR
pathway, which was confirmed by means of immunohisto-
chemistry in a further 48 dogs, and p53 associated genes.
Diﬀerentially expressed proteins were identified by applying
2D-DIGE to samples collected from prostate and bladder
carcinoma.97 A total of 230 proteins were found to be diﬀeren-
tially expressed between neoplastic cancerous and healthy
control tissues in prostate carcinoma, and 208 proteins were
identified in bladder cancer. Three proteins, namely t keratin 7,
GRP78, and endoplasmin, were found to be significantly over-
expressed in carcinomas after comparison with healthy pros-
tate or bladder. A glycoproteomic study on TCC was also carried
out. Eighteen distinct fucosylated peptides were similar in dogs
with TCC, 12 of which increased more than 50% in animals
with cancer, as compared to healthy controls.87
A proteomic characterisation of the canine urinary proteome
using LC-MS/MS identified 563 proteins, including 391 pro-
teins belonging to the exosomal fractions, 214 soluble proteins,
and 42 proteins that were found in both groups, paving the way
for future investigations in urinary cancer biomarkers.20 Meta-
bolomic analysis relying on 1H NMR-based metabolite profiling
was also carried out on urine of bladder cancer-aﬀected
animals.98 The study was carried out on cancer-aﬀected dogs,
and the results were compared with the urine of healthy
animals, allowing to identify six highly sensitive biomarkers,
including urea, choline, methylguanosine, citrate, acetone, and
b-hydroxybutyrate.
7. Osteosarcomas
Canine osteosarcoma is the most frequent bone primary
tumour in the dogs. Canine osteosarcoma exhibits very similar
gene expression profiles with human osteosarcoma,40 thus
providing a very good comparative model, in particular for
the paediatric form.99,100 Gene expression studies were carried
out to classify osteosarcoma aﬀected dogs at diagnosis in
‘‘poor’’ and ‘‘good’’ prognosis, with a survival time of less than
or more than 6 months, respectively.101 Two groups of animals
were identified, namely a short survival group, including dogs
with a poor prognosis and a survival rate of less than 6 months,
and a long survival group, including dogs with better prognosis,
with a survival rate of 6 months or longer. A number of 51
transcripts were found to be diﬀerentially expressed and hier-
archical clustering, validated by reverse transcriptase poly-
merase chain reaction (RT-PCR) analysis, revealed that four
genes, namely ANKRRD17, MGST1, MRPS31, and NCOR1, were
overexpressed in the short survival group. Expression profiling
following the same technique identified both biomarkers and
pathways associated with the clinical outcome102 in dogs that
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responded poorly to chemotherapy and dogs that responded
well, as defined by the disease-free intervals (o100 days
and 4300 days). Diﬀerentially expressed genes related to the
hedgehog signalling pathway, such as HHIP, were found to be
upregulated in the poor responder cohort.
Gene expression profiles can classify osteosarcoma cell
cultures in two molecular groups.103 Group 1 featured the
over-expression of 125 genes, involved in mitosis, chromosome
segregation, and mitotic spindle formation, and a group 2,
which overexpressed 157 genes associated to cell migration,
adhesion, angiogenesis, proliferation, inflammation, and
apoptosis. In vivo gene expression profiling of spontaneous
osteosarcoma confirmed diﬀerential gene expression signatures.
In a pioneer study, the use of gene expression prediction signa-
tures was recently applied aiming to predict chemosensitivity and
treatment outcomes in ostosarcoma.104 Co-expression extrapola-
tion (COXEN) method105 was applied, and canine microarray gene
expression data were integrated with human genomic data, and
both provided the base of the model to predict response to
doxorubicin and carboplatin in canine osteosarcoma, highlight-
ing the potential application of genomic methods to personalised
cancer therapy.
8. Other types of cancer
Gene profiling studies of other spontaneous tumours have been
carried out in dogs, although somehow sporadically. A custom
specific cDNA microarray, containing approximately 4000 clones
from canine brain cDNA, was used to diﬀerentiate primary
tumours in the central nervous system.106 The result highlighted
diﬀerences between meningiomas and normal meninges
(327 genes), and 564 genes diﬀerentiating meningiomas from
all other tumours. Microarray analysis was also applied to
support the diﬀerentiation of soft tissue sarcomas, a category
inclusive of tumours with diﬀerent histological origins, such as
fibrosarcomas and peripheral nerve sheath tumours (PNST).
Gene expression profiles were then applied to five dog fibro-
sarcomas and five PNST.107 The comparison of the transcrip-
tome revealed that 77 genes were diﬀerentially expressed,
of which 39 were found to be overexpressed in PNST and 38
were overexpressed in fibrosarcomas. The group of genes
upregulated in PNST included genes associated with neuronal
diﬀerentiation, as well as transcription factors, cytoskeletal
proteins, and membrane proteins. The group of genes upregu-
lated in fibrosarcomas coded for src homology 3 domain, or
were genes coding for membrane proteins, or protein involved
in oxidoreductase processes and transcriptional regulation. The
overexpression of the genes with highest expression—namely
CLEC3B, GLI1, and DOK4 for PNST, and FHL2, CSK, and PLAGL1
for fibrosarcomas—were validated and confirmed with RT-PCR.
Remarkably, the results of this study provided the background
for the development of a molecular assay to diﬀerentiate the two
tumours using a PCR approach with GLI1 and CLEC3B as mole-
cular targets.108 The canine is the only species where another
relevant tumour, the hemangiosarcoma, develops spontaneously
at specific locations such as the heart right auricle and the spleen.
Hemangiosarcomas account for up to 7% of malignant dog
tumours.64 A gene expression profiling approach demonstrated
that hemangiosarcoma is associated with the golden retriever
breed, and correlated with the upregulation of VEGFR1.8
The pathogenesis of hemangiosarcoma is not entirely clear.
In an isolated in vitro system, it was demonstrated that heman-
giosarcoma cells can be diﬀerentiated from nonmalignant splenic
hematoma cells by means of gene expression profiles.109 The
study identified a transcriptomic signature capable of diﬀerentiat-
ing hemangiosarcoma cells from nonmalignant endothelial cells
of splenic hematoma, and validated two genes, TIMP-1 and
PLZF. The identified signatures also allowed diﬀerentiation
of hemangiosarcomas from other malignancies, including
lymphoma, leukaemia, and osteosarcoma. Classification of
hemangiosarcomas is also an issue: microarray and RNA-seq
were applied to identify molecular and functional subtypes in
primary canine hemangiosarcomas.110 Three divergent mole-
cular subtypes were identified: group 1, associated with angio-
genesis and endothelia cell function; group 2, associated with
inflammation and myeloid diﬀerentiation; and group 3, asso-
ciated with adipogenesis sand lipid transport. Results were
confirmed in sphere-cultured cells, demonstrating that enriched
progenitor populations also display gene profile resembling that
of the three subgroups. A microarray-based transcriptomics has
also been applied to determine gene expression profiling of
insulinoma, which is the most common malignant pancreatic
endocrine cancer in dogs.111–113 The aim of the study was to
identify (a) the differences in genes that were differentially
expressed in primary insulinomas and their metastasis and (b)
the differences in genes expressed in two subsets of primary
insulinomas. Distinct clusters were identified: high-metastatic
groups could be differentiated by the downregulation of PNLIP,
CTRB1, and PA, as compared to the low-metastatic group. More-
over, a group of 84 genes were found to be downregulated in the
metastases, as compared to the primary tumour.
Gene expression profiling was used to study the pathogenesis
of histiocytic sarcomas, a rare cancer with high incidence in flat-
coated retriever.114 Spleen was chosen as the normal equivalent
for histiocytoma, and cancers located in defendant districts of the
bodies were compared to it by gene expression profiling. A total of
352 genes were found to be diﬀerentially expressed when compar-
ing visceral (lung, liver, kidney) histiocytoma with spleen and 319
genes were found to be diﬀerentially expressed when comparing
undefined locations (knee, shoulder, elbow) with spleen. Nine of
the 10 genes analysed were validated with quantitative PCR,
confirming that PPBP, SpiC, VCAM1, ENPEP, and ITGAD were
downregulated and GTSF1, LUM, Thy1, and Col3a1 were upregu-
lated in both soft tissue and visceral, as compared to normal
spleen. Out of the 11 gene that were analysed with RT-PCR, only
three, namely C6, CLEC12A, and CCL5, were found to be statisti-
cally significantly expressed between visceral and soft tissue-
localised histiocytic sarcomas.115
A microarray hybridisation comparative experiment high-
lighted the impact of epigenetic regulation of miRNA on tumour
suppression of human and dog melanoma.116 The expression of
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miR-520c-3p was found to be upregulated, and other six micro-
RNAs, namely miR-126, miR-200a, miR-203, miR-205, miR517b,
and miR-713, were downregulated. These findings provided the
background for the use of miR-203 and miR205 as cell growth
inhibitors of canine melanoma.
9. Unearthing treasures: omics
analyses from formalin-fixed,
paraﬃn-embedded tissues
Fixing pathological specimens with formalin and paraﬃn
embedding (FFPE) is routinely performed as the chosen proce-
dure to preserve tissue morphology. Snap frozen tissue samples
still provide the gold standard for omics analyses, but formalin-
free fixatives are available as a good alternative (Klopfleisch
et al., 2011118), enabling parallel histologic and molecular
analyses.117 Amplification of microRNA, 400-bp-long mRNA,
and 1000-bp-long DNA fragments118 was obtained following
this technique. Nevertheless, FFPE has been applied for storage
of tissues for over a century, and FFPE blocks may be the only
available sample type, providing archival specimens that repre-
sent an essential source of tissue for retrospective studies.
Protocols to extract both protein and nucleic acid material
from FFPE tissues have been therefore developed, in order to
apply omics to material from archival cases.
Embedding of samples in paraﬃn after formalin fixation
represents a serious challenge for protein extraction. Formal-
dehyde reacts with primary amines to form Schiﬀ bases, and
with amides to form hydroxymethyl compounds.119 DNA frag-
mentation also occurs, caused by low pH of unbuﬀered for-
maldehyde solutions, due to its oxidation to formic acid.120
Similar eﬀects have been reported for mRNA, where a complete
loss of poly A tails has been also reported.121 Consequently,
FFPE has negative eﬀects on the recovery and quality of
proteins and nucleic acids for omics analyses.122 The above
eﬀects results in failure of amplifying DNA fragments longer
than 200 bp,123 although amplification of up to 600 bp has been
reported, providing high yield of genomic DNA with high quality
from FFPE mast cells tumours and cutaneous histiocytomas.124
Storage of tissues in FFPE still provide several challenges for
RNA extraction. A recent study comparing DNA and RNA
isolation from canine oncologic FFPE provides less encoura-
ging results.125 RNA integrity number (RIN) was lower than 2.5,
and only minor and degraded amounts of RNA were recovered
from FFPE tissues, confirming previous studies in human
tissues.126 Contrary to mRNA extraction, consistent microRNA
profiles between frozen and FFPE specimens for the purpose of
NGS analyses have been obtained; this good yield may be
associated either with the small size of microRNA, or with the
way in which these molecules are stored in the cell.127 In
veterinary medicine, microRNAs have been extracted and quan-
tified by RT-PCR from FFPE tissue, with an apparent good yield
and quality.128 A recent protocol demonstrated that using
archived clinical samples for exome sequencing and miRNA
and mRNA profiling of 12 FFPE tumour tissues is feasible,129
identifying p53 and Rb protein as the most mutated genes.
The impact on proteome stability by preserving samples
in RNAlater (Thermo Fisher Scientific, Waltham, MA) prior to
formalin fixation and paraﬃn embedding on human soft
tissues, using directly frozen samples as a control, has been
recently presented.130 In a model of dog liver, a protocol
combining full-length protein extraction and GeLC-MS/MS
analyses on FFPE tissues was developed. Parallel GeLC-MS/MS
analyses on FFPE and snap frozen tissues from caninemammary
tumours were then carried out.131 Results demonstrated that
FFPE samples delivered less data, in particular for what concerns
high molecular weight proteins. Nonetheless, proteomics results
from frozen samples largely converge toward those from FFPE,
confirming the informational power of proteomics techniques
applied to retrospective cancer research utilising FFPE extracts.
Laser capture microdissection (LCM) provides a valuable
tool for the enrichment of a specific cell type within complex
tissue samples, and downstream techniques for omics analyses
have been developed.132 In humans, LC-MS workflows have
been developed to obtain laser-captured microdissected patholo-
gic tissues in several diseases, such as colon adenocarcinoma,133
breast cancer,134 and heart infarction.135 Intact proteins, such as
prostate-specific antigen (PSA), have been identified by these
techniques,136 as well as proteins obtained from sclerotic lesions
(human glomerular disease),137 amyloid, or other conformation
involving a loss of solubility of proteins and peptides.138 To the
best knowledge of the authors, the pairing of laser dissection to
proteomics has not been applied to veterinary medicine. Reasons
are likely economic, but we believe that due to the decreasing cost
of this technology, the application of this technique to veterinary
diagnostics in the near future is highly probable.
10. Conclusions and future
perspectives
This paper reviewed the state of knowledge on the application
of omics technologies to canine cancer studies. The number of
transcriptomic and proteomics studies carried out in dog pales
if compared to those carried out in humans and only a few
types of dog cancers have been characterised so far by means of
omics techniques. Therefore, several issues remain to be
addressed, and most of the molecular pathways and complex
gene expression patterns driving cancer in dogs remain undi-
sclosed. In human medicine, clinical sequencing of tumours
might soon become routine in oncology. Technology moves
rapidly forward and the costs for omics application is con-
stantly dropping. The goal of a $1000 genome139 has been
almost reached, and it is expected that further drops in omics
experiment costs will result in an exponential increase of
transcriptomics and proteomic studies, which will likely be
extended to other omics disciplines such as glycomics and
metabolomics in veterinary medicine. Although the perspective
of the evaluation of the single patient in veterinary oncology
routine practice might appear somehow futuristic in veterinary
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medicine, recent studies have introduced the concept of perso-
nalised medicine in veterinary therapy as well.10,67,104,140 There-
fore, the application of omics and system biology disciplines in
veterinary routine practices does not seem that far anymore.
List of abbreviations
2D/MS 2D gel electrophoresis/mass spectrometry
2-DIGE/MS 2-D fluorescence diﬀerence gel electrophor-
esis/mass spectrometry
2D/MALDI-TOF 2D gel electrophoresis/matrix-assisted laser
desorption ionisation-time of flight
2-DIGE 2-D fluorescence diﬀerence gel electrophoresis
2-DGE 2-Dimensional gel electrophoresis
LC-MS/MS Liquid chromatography-mass spectrometry
MALDI-TOF Matrix-assisted laser desorption ionisation-
time of flight
NGS Next generation sequencing
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